29 results
Thumbnail

D1.111 - Tezepelumab reduces in patients with severe allergic asthma and rhinoconjunctivitis not only bronchial but also nasal and conjunctival symptoms – results from an exposure chamber study

Thumbnail

D1.112 - ILC2 Expansion as a Biomarker of Suboptimal Response to Dupilumab in Severe Asthma: Findings from the PRISM Study

Thumbnail

D1.113 - Effect of mepolizumab in eosinophilic granulomatosis with polyangiitis (EGPA): a real-world retrospective observational study

Thumbnail

D1.114 - Efficacy of Radical Endoscopic Surgery Combined with Mepolizumab in Chronic Rhinosinusitis with Nasal Polyps Complicated with Bronchial Asthma: A Real-World research

Thumbnail

D1.115 - Real World Assessment of Uncontrolled Severe Asthma in Canada - A Multi-Site Qualitative Survey of Type 2 Inflammatory Biomarkers and Clinical Outcomes

Thumbnail

D1.119 - Care pathways and systemic steroid (over)use in chronic rhinosinusitis with nasal polyps (CRSwNP) in Germany

Thumbnail

D1.120 - Genetic Associations with Asthma in the Kazakh Population: A Case–Control Study

Thumbnail

D1.121 - Association of Serum Club Cell Secretory Protein 16 (CC16) with House Dust Mite Sensitization in Children with Asthma

Thumbnail

D1.122 - Inspiratory and expiratory airway resistance and expiratory flow limitation in patients with asthma and in response to biological treatment in asthma